[
  {
    "ts": "2026-01-23T09:14:02+00:00",
    "headline": "Assessing Kenvue (KVUE) After Its Separation From Johnson & Johnson",
    "summary": "If you are wondering whether Kenvue is priced attractively right now, this article will walk you through what the current share price may be implying about its value. Kenvue's stock recently closed at US$17.75, with returns of 2.8% over 7 days, 4.3% over 30 days, 2.5% year to date, and a 10.9% decline over the past year. These moves can signal changing views on both its potential and its risks. Recent headlines have focused on Kenvue as an independent consumer health company following its...",
    "url": "https://finance.yahoo.com/news/assessing-kenvue-kvue-separation-johnson-091402460.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "295b4b37-707e-305c-8e37-072c5c8973d2",
      "content": {
        "id": "295b4b37-707e-305c-8e37-072c5c8973d2",
        "contentType": "STORY",
        "title": "Assessing Kenvue (KVUE) After Its Separation From Johnson & Johnson",
        "description": "",
        "summary": "If you are wondering whether Kenvue is priced attractively right now, this article will walk you through what the current share price may be implying about its value. Kenvue's stock recently closed at US$17.75, with returns of 2.8% over 7 days, 4.3% over 30 days, 2.5% year to date, and a 10.9% decline over the past year. These moves can signal changing views on both its potential and its risks. Recent headlines have focused on Kenvue as an independent consumer health company following its...",
        "pubDate": "2026-01-23T09:14:02Z",
        "displayTime": "2026-01-23T09:14:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d690536de0c7b23c26cf14ed9066767e",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2Y4xgPz6k2sJssKwLaiuQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d690536de0c7b23c26cf14ed9066767e.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XxQ2W.u4ql9pr6kIHenw7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d690536de0c7b23c26cf14ed9066767e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-kenvue-kvue-separation-johnson-091402460.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-kenvue-kvue-separation-johnson-091402460.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T10:04:00+00:00",
    "headline": "Is This Dividend King a Screaming Buy?",
    "summary": "Maybe there won't be any screaming about this stock. But there could be some buying.",
    "url": "https://www.fool.com/investing/2026/01/23/is-this-dividend-king-a-screaming-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6a1b445c-fa47-3100-b561-036d308d2d36",
      "content": {
        "id": "6a1b445c-fa47-3100-b561-036d308d2d36",
        "contentType": "STORY",
        "title": "Is This Dividend King a Screaming Buy?",
        "description": "",
        "summary": "Maybe there won't be any screaming about this stock. But there could be some buying.",
        "pubDate": "2026-01-23T10:04:00Z",
        "displayTime": "2026-01-23T10:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/f1c1863f7dea2f4e8bc3395db42117e0",
          "originalWidth": 1400,
          "originalHeight": 840,
          "caption": "A person wearing a white coat with Johnson & Johnson above the pocket drawing on glass.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1jxSU31M1ZkXeae5qamKgA--~B/aD04NDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/f1c1863f7dea2f4e8bc3395db42117e0.cf.webp",
              "width": 1400,
              "height": 840,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/121_35_bCg3eCRaknA_FDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/f1c1863f7dea2f4e8bc3395db42117e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/is-this-dividend-king-a-screaming-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dividend-king-screaming-buy-100400268.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T12:30:05+00:00",
    "headline": "Pharma: J&J's broadening product pipeline can bring 'new era'",
    "summary": "Johnson & Johnson (JNJ) topped fourth quarter revenue estimates while forecasts for full-year 2026 outpaced Wall Street expectations. Guggenheim Securities senior research analyst and managing director Vamil Divan — who has a Buy rating on J&J stock — discusses the pharmaceutical giant's narratives around its latest products and old IP (intellectual properties). Also catch Vamil Divan talk about his outlook on Johnson & Johnson for 2026. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
    "url": "https://finance.yahoo.com/video/pharma-j-js-broadening-product-123005510.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "010e8be5-c834-3caa-801e-243ab27d71e2",
      "content": {
        "id": "010e8be5-c834-3caa-801e-243ab27d71e2",
        "contentType": "VIDEO",
        "title": "Pharma: J&J's broadening product pipeline can bring 'new era'",
        "description": "<p>Johnson & Johnson (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>) topped<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/news/live/earnings-live-netflix-stock-tumbles-johnson--johnson-falls-halliburton-and-united-airlines-climb-125813797.html\"> fourth quarter revenue estimates</a> while forecasts for full-year 2026 outpaced Wall Street expectations.</p>\n<p>Guggenheim Securities senior research analyst and managing director Vamil Divan — who has a Buy rating on J&J stock — discusses the pharmaceutical giant's narratives around its latest products and old IP (intellectual properties).</p>\n<p>Also catch Vamil Divan talk about <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/video/j-js-2026-guidance-driven-163037241.html\">his outlook on Johnson & Johnson</a> for 2026.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Johnson & Johnson (JNJ) topped fourth quarter revenue estimates while forecasts for full-year 2026 outpaced Wall Street expectations. Guggenheim Securities senior research analyst and managing director Vamil Divan — who has a Buy rating on J&J stock — discusses the pharmaceutical giant's narratives around its latest products and old IP (intellectual properties). Also catch Vamil Divan talk about his outlook on Johnson & Johnson for 2026. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
        "pubDate": "2026-01-23T12:30:05Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/d3592b40-f6e7-11f0-bbfb-94770ea279b0",
          "originalWidth": 7952,
          "originalHeight": 4480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4zC2SSTcTNKTbqkfiYr28g--~B/aD00NDgwO3c9Nzk1MjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/d3592b40-f6e7-11f0-bbfb-94770ea279b0.cf.webp",
              "width": 7952,
              "height": 4480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5ZqPw1W1Y5NC1_ywTko2tQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/d3592b40-f6e7-11f0-bbfb-94770ea279b0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/pharma-j-js-broadening-product-123005510.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/pharma-j-js-broadening-product-123005510.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]